There has been interest in using progression-free survival as a surrogate endpoint for overall survival in oncology clinical trials. In order to objectively define this endpoint, clear understanding of what progression means, how it is measured and what its implications are need to be discussed. This article discusses some regulatory aspects of using progression-free survival as an endpoint.
Get full access to this article
View all access options for this article.
References
1.
Dagher R, Johnson J., Williams G., Keegan P., Pazdur R.Accelerated approval of oncology products: a decade of experience. Journal Of National Cancer Institute2004; 96: 1500-09.
2.
Johnson J, Williams G., Pazdur R.Endpoints and United States Food and Drug Administration Approval of Oncology Drugs. Journal of Clinical Oncology2003; 21: 1404-11.
3.
Code of Federal Register - 21 CFR 314 and 601. Accelerated Approval Rule, 1992.
4.
Oncology Drugs Advisory Committee meeting. Retrieved 16 December 2003, from http://www.fda.gov/ohrms/dockets/ac/cder03. html#OncologicDrugs
5.
Guidance to industry - clinical trial endpoints for the approval of cancer drugs and biologics. Retrieved (n.d.), from http://www.fda.gov/cder/guidance/ 6592dft.htm
6.
Oncology Drugs Advisory Committee meeting. Retrieved 3 May 2004, from http://www.fda.gov/ohrms/dockets/ac/cder04. html#OncologicDrugs
7.
Kane RC, Farrell AT, Saber H., Tang S., Williams G., Jee JM, Liang C., Booth B., Chidambaram N., Morse D., Sridhara R., Garvey P., Justice R., Pazdur R.Sorafenib for the treatment of advanced renal cell carcinoma. Clinical Cancer Research2006 ; 12: 7271-78.
